Global Chemiluminescence Immunoassay (CLIA) Market Size (2024 - 2029)

The chemiluminescence immunoassay analyzers market is projected to experience growth due to the increasing demand for reliable diagnostic methods, particularly highlighted by the pandemic's impact on testing needs. The versatility of chemiluminescence immunoassay (CLIA) in various fields such as clinical diagnosis, environmental monitoring, and pharmaceutical analysis, coupled with its enhanced sensitivity and specificity, is driving its adoption. Additionally, the rising prevalence of chronic diseases is prompting researchers to utilize CLIA for more accurate disease mechanism detection, further contributing to market expansion. However, the market's growth may be impeded by a shortage of skilled professionals capable of operating these advanced methods.

Market Size of Global Chemiluminescence Immunoassay (CLIA) Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Chemiluminescence Immunoassay (CLIA) Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
CAGR 6.60 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Chemiluminescence Immunoassay (CLIA) Market Major Players

*Disclaimer: Major Players sorted in no particular order

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Chemiluminescence Immunoassay (CLIA) Market Analysis

The chemiluminescence immunoassay market is expected to grow at a CAGR of 6.6% during the forecast period (2022-2027).

The Covid-19 pandemic is anticipated to have a considerable impact on the studied market. During the initial phase of the pandemic due to strict lockdown and shut down the laboratories, diagnostic centers, and research units were closed, so there was a decline in the number of assays performed, which hampered the market growth. However, soon after the situation stabilized population across the globe returned to work and it was critical to develop tests that reliably detect SARS-CoV-2-specific antibodies. Hence researchers started procuring different assays for the detection of the virus. For instance, research conducted by a group of scientists in the United States presented their results from a multiplex serology test for assessing the antibody responses to COVID-19. And their research was published in February 2021 titled 'A multiplex chemiluminescent immunoassay for serological profiling of COVID-19-positive symptomatic and asymptomatic patients'. As per the research article, the chemiluminescent immunoassay (CLIA) can demonstrate high clinical sensitivity and specificity and can reliably be used to diagnose infection by SARS-CoV-2. Such research provided information on the efficiency of the CLIA tests, which is expected to impact the demand for CLIA methods. Therefore, the pandemic is expected to have a significant impact on the market studied.

The chemiluminescence immunoassay (CLIA) has been applied in different fields including environmental monitoring, liquid chromatography, clinical diagnosis, food safety, pharmaceutical analysis, immuno-, and gene probe assays, as a promising approach for selective, sensitive, rapid, and simple analysis. The article 'Detection of Circulating varicella-zoster virus (VZV)-Glycoprotein E (gE)-Specific Antibodies by Chemiluminescent Immunoassay (CLIA) for Varicella-Zoster Diagnosis' published in January 2022 stated that the CLIA approach-based detection kit for diagnosing VZV-gE-specific IgA (immunoglobulin-A), IgG (immunoglobulin-G), and IgM (immunoglobulin-M) is simple, and suitable for high-throughput routine analysis situations, also provides enhanced specificity compared to ELISA (enzyme-linked immunoassay). Thus, such research providing positive results of CLIA methods is anticipated to drive market growth.

Furthermore, chronic diseases such as cancer, cardiovascular diseases, diabetes, Alzheimer's diseases, and respiratory disorders are increasing day by day globally. And the detection of the mechanism behind the disease is crucial to further accelerate the drug development and treatment process. Thus, scientists are recently adopting the CLIA method for such research purposes. The research article 'Machine Learning Reveals a Multipredictor Nomogram for Diagnosing the Alzheimer's Disease Based on Chemiluminescence Immunoassay for Total Tau in Plasma' published in May 2022 stated that the researchers established a direct standard CLIA curve under optimized conditions for total tau detection in Alzheimer's patients and the results showed that CLIA provided fairly repeatability and reliability compared to other detection technologies. Such reliability of the detection method is creating demand for the use of the methods, thereby contributing to the growth of the market studied.

Therefore, owing to the aforesaid factors the studied market is predicted to witness growth over the forecast period. However, the lack of skilled professionals to handle these methods is anticipated to hinder market growth over the forecast period.

Chemiluminescence Immunoassay (CLIA) Industry Segmentation

As per the scope of the report, chemiluminescence (CL) is described as the discharge of electromagnetic radiation owing to the production of light by a chemical reaction. Chemiluminescence immunoassay (CLIA) is an assay incorporating the technique of chemiluminescence with immunochemical reactions. The chemiluminescence immunoassay (CLIA) market is segmented by Product Type (Analyzers, Reagents, and Consumables), Application (Oncology, Autoimmune Disorder, Infectious Disease, Cardiovascular Disease, Endocrine Disorders and Others), End-User (Pharmaceutical and Biotechnology Companies, Hospital and Clinical Laboratories and Others), and Geography (North America, Europe, Asia Pacific, Middle East, and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Product Type
Analyzers
Automated
Semi-Automated
Reagents
Luminophore Markers
Enzymatic Markers
Consumables
By Application
Oncology
Autoimmune Disorder
Infectious Disease
Cardiovascular Disease
Endocrine Disorders
Others
By End User
Pharmaceutical and Biotechnology Companies
Hospital and Clinical Laboratories
Others
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Global Chemiluminescence Immunoassay (CLIA) Market Size Summary

The chemiluminescence immunoassay (CLIA) market is poised for significant growth, driven by its applications across various fields such as clinical diagnosis, environmental monitoring, and pharmaceutical analysis. The market's expansion is supported by the increasing prevalence of chronic diseases like cancer and cardiovascular disorders, which necessitate advanced diagnostic methods. The COVID-19 pandemic initially hindered market growth due to laboratory shutdowns, but it also spurred demand for CLIA methods as researchers sought reliable tests for SARS-CoV-2 detection. This shift highlighted the efficiency of CLIA tests, contributing to their growing adoption. The market is characterized by moderate competition, with major players like F. Hoffmann-La Roche AG and Siemens Healthineers AG leading through strategic acquisitions and product innovations.

North America is expected to dominate the CLIA market, driven by the high incidence of chronic diseases and advancements in diagnostic technologies. The United States, in particular, shows a rising demand for effective diagnosis and treatment methods due to the increasing burden of diseases such as melanoma and coronary artery conditions. The market's growth is further bolstered by ongoing research and development, which continues to validate the efficacy of CLIA methods in oncology and other areas. Despite challenges like the shortage of skilled professionals, the market is anticipated to expand, supported by the continuous introduction of innovative products and solutions.

Explore More

Global Chemiluminescence Immunoassay (CLIA) Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Rising Incidence of Chronic Diseases

      2. 1.2.2 Increasing Technological Advancements

    3. 1.3 Market Restraints

      1. 1.3.1 Lack of Skilled Professionals

    4. 1.4 Porter's Five Force Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 2.1 By Product Type

      1. 2.1.1 Analyzers

        1. 2.1.1.1 Automated

        2. 2.1.1.2 Semi-Automated

      2. 2.1.2 Reagents

        1. 2.1.2.1 Luminophore Markers

        2. 2.1.2.2 Enzymatic Markers

      3. 2.1.3 Consumables

    2. 2.2 By Application

      1. 2.2.1 Oncology

      2. 2.2.2 Autoimmune Disorder

      3. 2.2.3 Infectious Disease

      4. 2.2.4 Cardiovascular Disease

      5. 2.2.5 Endocrine Disorders

      6. 2.2.6 Others

    3. 2.3 By End User

      1. 2.3.1 Pharmaceutical and Biotechnology Companies

      2. 2.3.2 Hospital and Clinical Laboratories

      3. 2.3.3 Others

    4. 2.4 Geography

      1. 2.4.1 North America

        1. 2.4.1.1 United States

        2. 2.4.1.2 Canada

        3. 2.4.1.3 Mexico

      2. 2.4.2 Europe

        1. 2.4.2.1 Germany

        2. 2.4.2.2 United Kingdom

        3. 2.4.2.3 France

        4. 2.4.2.4 Italy

        5. 2.4.2.5 Spain

        6. 2.4.2.6 Rest of Europe

      3. 2.4.3 Asia-Pacific

        1. 2.4.3.1 China

        2. 2.4.3.2 Japan

        3. 2.4.3.3 India

        4. 2.4.3.4 Australia

        5. 2.4.3.5 South Korea

        6. 2.4.3.6 Rest of Asia-Pacific

      4. 2.4.4 Middle-East and Africa

        1. 2.4.4.1 GCC

        2. 2.4.4.2 South Africa

        3. 2.4.4.3 Rest of Middle-East and Africa

      5. 2.4.5 South America

        1. 2.4.5.1 Brazil

        2. 2.4.5.2 Argentina

        3. 2.4.5.3 Rest of South America

Global Chemiluminescence Immunoassay (CLIA) Market Size FAQs

The Global Chemiluminescence Immunoassay (CLIA) Market is projected to register a CAGR of 6.60% during the forecast period (2024-2029)

DiaSorin S.p.A., Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Siemens Healthineers AG, Danaher (Beckman Coulter Inc.) and F. Hoffmann-La Roche are the major companies operating in the Global Chemiluminescence Immunoassay (CLIA) Market.

Chemiluminescence Immunoassay Analyzers Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)